Takeda Pharmaceutical is selling its subsidiary in Japan focused on consumer healthcare to US investment fund Blackstone Group.
The deal, announced Monday, August 24, by the Japanese drugs manufacturer, is valued at 242 billion yen (US$2.3 billion), although the exact sales price will be determined later, after adjustments for debt and capital of the subsidiary, Takeda Consumer Healthcare.
The deal will likely be completed by March 2021, according to Tokyo-based Takeda. Takeda stated it wants to focus on specialized areas, such as disorders of the digestive system, rare diseases, plasma-derived therapies, and the prevention and treatment of cancer, rather than the increasingly competitive consumer sector.
The subsidiary, spun off in 2017, sells drugs popular in Japan called Alinamin, a type of vitamin supplement, and Bendex, a cold remedy.
Blackstone plans to develop the business and retain all the workers, Takeda’s statement said.
Takeda, among the global companies working on a treatment for COVID-19, expects the sale to boost its net profit by about 105 billion yen (US$1 billion).
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
